SCHEMBL7039286

SCHEMBL7039286

Cc1ccccc1C(=S)c1ccc(Nc2ncccc2Br)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 2/20 0.46
MAPK14 Q16539 8/20 0.46
MAPK13 O15264 7/20 0.46
MAPK12 P53778 7/20 0.46
MAPK11 Q15759 7/20 0.46
NPC1 O15118 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.43
GRM4 Q14833 4/20 0.43
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7037194 0.87 MAPK13 (0.63) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL7037212 0.87 MAPK14 (0.52) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL7037822 0.85 MAPK14 (0.44) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL7033514 0.83 MAPK14 (0.51) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL7037190 0.83 MAPK14 (0.44) SMN1; SMN2MAPTMAPK14MAPK13MAPK12
SCHEMBL1907094 0.82 MAPK14 (0.58) MEN1KMT2AMAPTMAPK14MAPK13
SCHEMBL7039477 0.82 MAPK13 (0.57) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL7032178 0.81 MAPK14 (0.49) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL1907237 0.80 MAPK14 (0.59) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL7037778 0.79 MAPK14 (0.52) RAB9AMEN1KMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US claimed
EP-1289958-A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) Leo Pharma A/S (DK) 2003-03-12 EP disclosed
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US disclosed
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-02-07 US disclosed
WO-2001090074-A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha IL1B, IL1A, NFKBIA RAB9A 3591/4885MEN1 4019/4885KMT2A 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.